Tags

Type your tag names separated by a space and hit enter

The HEART study: a real-world experience using the CID Chrono Carbostent in primary and rescue PCI.
J Cardiovasc Med (Hagerstown). 2012 Dec; 13(12):775-82.JC

Abstract

BACKGROUND

Chrono Carbostent (CID, Saluggia, Italy) is characterized by a peculiar coating with Carbofilm which could reduce the risk of thrombosis as compared to other bare metal stents (BMS). This feature should be particularly useful in the setting of primary or rescue percutaneous coronary intervention (PCI) in patients with ST-segment elevation myocardial infarction (STEMI).

METHODS

We tested the efficacy and safety of this stent in patients with STEMI undergoing primary or rescue PCI. Inclusion criteria included the diagnosis of STEMI, a coronary anatomy suitable for stenting and no contraindications to dual antiplatelet therapy for at least 1 month. The primary endpoint was the composite of the following major adverse cardiac events (MACEs) at 12 months: death, recurrence of myocardial infarction and target vessel revascularization.

RESULTS

One hundred and seven STEMI patients treated with Chrono Carbostent implantation were enrolled. Eighty-three (77%) patients underwent primary and 24 (23%) rescue PCI. A total of 148 stents were successfully implanted. Cardiogenic shock was present in 12 (11%) patients and in-hospital mortality was 6.5%. Cumulatively, the rate of MACEs at 12 months was 17.7% (deaths 7.4%, target lesion revascularization 9.3%).

CONCLUSIONS

In unselected patients with STEMI treated by urgent PCI, the Chrono Carbostent showed a low rate of events in those patients surviving the acute phase of myocardial infarction. Unfortunately, and especially for patients in cardiogenic shock, survival continued to be relatively independent of interventional treatment, even when successfully completed, thus strictly linking prognosis of STEMI to severity of clinical presentation.

Authors+Show Affiliations

Institute of Cardiology, Catholic University of the Sacred Heart, Rome, Italy. antoniomarialeone@yahoo.itNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

22048665

Citation

Leone, Antonio Maria, et al. "The HEART Study: a Real-world Experience Using the CID Chrono Carbostent in Primary and Rescue PCI." Journal of Cardiovascular Medicine (Hagerstown, Md.), vol. 13, no. 12, 2012, pp. 775-82.
Leone AM, Sgueglia GA, Porto I, et al. The HEART study: a real-world experience using the CID Chrono Carbostent in primary and rescue PCI. J Cardiovasc Med (Hagerstown). 2012;13(12):775-82.
Leone, A. M., Sgueglia, G. A., Porto, I., Niccoli, G., Burzotta, F., Trani, C., De Caterina, A. R., Buffon, A., Mazzari, M. A., Mongiardo, R., Rebuzzi, A. G., & Crea, F. (2012). The HEART study: a real-world experience using the CID Chrono Carbostent in primary and rescue PCI. Journal of Cardiovascular Medicine (Hagerstown, Md.), 13(12), 775-82. https://doi.org/10.2459/JCM.0b013e32834102d8
Leone AM, et al. The HEART Study: a Real-world Experience Using the CID Chrono Carbostent in Primary and Rescue PCI. J Cardiovasc Med (Hagerstown). 2012;13(12):775-82. PubMed PMID: 22048665.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The HEART study: a real-world experience using the CID Chrono Carbostent in primary and rescue PCI. AU - Leone,Antonio Maria, AU - Sgueglia,Gregory Angelo, AU - Porto,Italo, AU - Niccoli,Giampaolo, AU - Burzotta,Francesco, AU - Trani,Carlo, AU - De Caterina,Alberto Ranieri, AU - Buffon,Antonino, AU - Mazzari,Mario Attilio, AU - Mongiardo,Rocco, AU - Rebuzzi,Antonio Giuseppe, AU - Crea,Filippo, PY - 2011/11/4/entrez PY - 2011/11/4/pubmed PY - 2013/5/10/medline SP - 775 EP - 82 JF - Journal of cardiovascular medicine (Hagerstown, Md.) JO - J Cardiovasc Med (Hagerstown) VL - 13 IS - 12 N2 - BACKGROUND: Chrono Carbostent (CID, Saluggia, Italy) is characterized by a peculiar coating with Carbofilm which could reduce the risk of thrombosis as compared to other bare metal stents (BMS). This feature should be particularly useful in the setting of primary or rescue percutaneous coronary intervention (PCI) in patients with ST-segment elevation myocardial infarction (STEMI). METHODS: We tested the efficacy and safety of this stent in patients with STEMI undergoing primary or rescue PCI. Inclusion criteria included the diagnosis of STEMI, a coronary anatomy suitable for stenting and no contraindications to dual antiplatelet therapy for at least 1 month. The primary endpoint was the composite of the following major adverse cardiac events (MACEs) at 12 months: death, recurrence of myocardial infarction and target vessel revascularization. RESULTS: One hundred and seven STEMI patients treated with Chrono Carbostent implantation were enrolled. Eighty-three (77%) patients underwent primary and 24 (23%) rescue PCI. A total of 148 stents were successfully implanted. Cardiogenic shock was present in 12 (11%) patients and in-hospital mortality was 6.5%. Cumulatively, the rate of MACEs at 12 months was 17.7% (deaths 7.4%, target lesion revascularization 9.3%). CONCLUSIONS: In unselected patients with STEMI treated by urgent PCI, the Chrono Carbostent showed a low rate of events in those patients surviving the acute phase of myocardial infarction. Unfortunately, and especially for patients in cardiogenic shock, survival continued to be relatively independent of interventional treatment, even when successfully completed, thus strictly linking prognosis of STEMI to severity of clinical presentation. SN - 1558-2035 UR - https://www.unboundmedicine.com/medline/citation/22048665/The_HEART_study:_a_real_world_experience_using_the_CID_Chrono_Carbostent_in_primary_and_rescue_PCI_ L2 - http://dx.doi.org/10.2459/JCM.0b013e32834102d8 DB - PRIME DP - Unbound Medicine ER -